Equities research analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report $45.04 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for ACADIA Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $44.43 million and the highest estimate coming in at $45.60 million. ACADIA Pharmaceuticals posted sales of $11.96 million during the same quarter last year, which suggests a positive year over year growth rate of 276.6%. The business is expected to report its next earnings report on Tuesday, February 27th.
On average, analysts expect that ACADIA Pharmaceuticals will report full-year sales of $45.04 million for the current fiscal year, with estimates ranging from $125.77 million to $126.90 million. For the next year, analysts forecast that the firm will report sales of $247.03 million per share, with estimates ranging from $210.60 million to $270.00 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.10. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. The business had revenue of $35.58 million during the quarter, compared to analysts’ expectations of $32.03 million. During the same period last year, the company posted ($0.61) EPS. The business’s revenue was up 571.3% on a year-over-year basis.
ACADIA Pharmaceuticals (NASDAQ ACAD) opened at $27.00 on Wednesday. ACADIA Pharmaceuticals has a 52 week low of $24.31 and a 52 week high of $41.20.
ILLEGAL ACTIVITY NOTICE: “ACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $45.04 Million” was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/15/acadia-pharmaceuticals-inc-acad-expected-to-announce-quarterly-sales-of-45-04-million.html.
In related news, EVP Glenn Baity sold 37,500 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $40.91, for a total transaction of $1,534,125.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.25% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. San Francisco Sentry Investment Group CA bought a new stake in ACADIA Pharmaceuticals during the 2nd quarter valued at about $125,000. Oppenheimer Asset Management Inc. lifted its holdings in ACADIA Pharmaceuticals by 10.0% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 5,133 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 468 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in ACADIA Pharmaceuticals by 138.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,384 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 2,548 shares in the last quarter. Turner Investments LLC bought a new stake in ACADIA Pharmaceuticals during the 3rd quarter valued at about $188,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ACADIA Pharmaceuticals by 43.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,670 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 1,710 shares in the last quarter. Institutional investors own 95.27% of the company’s stock.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.